Table 3.
Patient characteristics associated with statin and ACEI/ARB prescribing at in-person office visits at 10 community health centers in Oregon where the medication(s) was/were clinically indicateda, June 2011 to May 2014
| Office visitsb where a statin indicated | Office visitsb where an ACEI/ARB was indicated | |||||
|---|---|---|---|---|---|---|
| Number of encountersc | % with an statin Rx < = 2 days | p-value | Number of encountersc | % with an ACEI/ARBs Rx < = 2 days | p-value | |
| Total | 11588 | (13.2) | 9887 | (15.8) | ||
| Patient characteristics | ||||||
| Sex | <.0001 | <.0001 | ||||
| Male | 4198 | (15.7) | 3819 | (17.9) | ||
| Female | 7390 | (11.8) | 6068 | (14.5) | ||
| Age | <.0001 | 0.0607 | ||||
| 18–39 | 1582 | (12.2) | 747 | (17.9) | ||
| 40–54 | 3060 | (15.5) | 2473 | (16.7) | ||
| 55–75 | 6946 | (12.5) | 6667 | (15.3) | ||
| Race/ethnicity | <.0001 | <.0001 | ||||
| Hispanic | 3721 | (17.7) | 2714 | (22.2) | ||
| Non-Hispanic White | 5460 | (10.8) | 5035 | (12.5) | ||
| Non-Hispanic Other | 2298 | (11.7) | 2032 | (15.4) | ||
| Missing/Unknown | 109 | (13.8) | 106 | (20.8) | ||
| Language | <.0001 | <.0001 | ||||
| English | 6918 | (10.7) | 6016 | (13.0) | ||
| Spanish | 3303 | (18.3) | 2401 | (23.1) | ||
| Other | 1321 | (13.6) | 1435 | (15.4) | ||
| Missing/Unknown | 46 | (10.9) | 35 | (20.0) | ||
| % of Federal Poverty Level at encounter | 0.0293 | 0.2398 | ||||
| < 100% | 8568 | (12.9) | 7294 | (15.5) | ||
| 100–199% | 2177 | (13.1) | 1888 | (16.3) | ||
| > = 200% | 751 | (16.8) | 639 | (17.8) | ||
| Missing/Unknown | 92 | (12.0) | 66 | (21.2) | ||
| Insurance at encounter | <.0001 | <.0001 | ||||
| Uninsured | 3817 | (18.2) | 2542 | (26.1) | ||
| Insured | 7759 | (10.8) | 7330 | (12.3) | ||
| Missing/Unknown | 12 | - | 15 | - | ||
| Patient smoking status | 0.042 | <.0001 | ||||
| Not current smoker | 8917 | (13.6) | 7448 | (16.7) | ||
| Current smoker | 2631 | (11.8) | 2403 | (12.6) | ||
| Missing/Unknown | 40 | (17.5) | 36 | (47.2) | ||
| Patient has active diagnosis of CVD | 0.0015 | <.0001 | ||||
| No CVD | 9984 | (13.6) | 7813 | (17.6) | ||
| Has CVD | 1604 | (10.7) | 2074 | (9.2) | ||
| Patient has active diagnosis of HTN | 0.1494 | 0.3498 | ||||
| No HTN | 5316 | (13.7) | 4026 | (15.4) | ||
| Has HTN | 6272 | (12.8) | 5861 | (16.1) | ||
| Patient has active diagnosis of liver disease | <.0001 | <.0001 | ||||
| No liver disease | 9946 | (13.9) | 8572 | (16.5) | ||
| Has liver disease | 1642 | (9.1) | 1315 | (11.3) | ||
| Patient has active diagnosis of kidney disease | <.0001 | <.0001 | ||||
| No kidney disease | 10759 | (13.6) | 8614 | (17.3) | ||
| Has kidney disease | 829 | (8.1) | 1273 | (6.3) | ||
| BMI | 0.2842 | 0.0009 | ||||
| < 25 | 1266 | (13.8) | 1333 | (12.5) | ||
| > = 25 | 9914 | (13.2) | 8251 | (16.3) | ||
| Missing/Unknown | 408 | (10.8) | 303 | (18.8) | ||
| BP control | 0.1188 | <.0001 | ||||
| < 120/80 | 3174 | (12.4) | 2834 | (9.4) | ||
| 120/80 to 139/89 | 6375 | (13.1) | 5291 | (15.2) | ||
| 140/90 to 159/99 | 1702 | (14.7) | 1459 | (26.6) | ||
| > = 160/100 | 334 | (15.3) | 301 | (35.5) | ||
| Missing/Unknown | 3 | (33.3) | 2 | - | ||
| HbA1c control | <.0001 | <.0001 | ||||
| < 7 | 5115 | (10.3) | 4398 | (12.8) | ||
| > = 7 | 6197 | (15.7) | 5192 | (18.4) | ||
| Missing/Unknown | 276 | (11.6) | 297 | (16.5) | ||
| LDL control | <.0001 | <.0001 | ||||
| < =100 or missing | 4744 | (9.6) | 5867 | (14.3) | ||
| 100 to 129 | 4163 | (13.7) | 2194 | (18.0) | ||
| > = 130 | 2681 | (18.9) | 1826 | (18.1) | ||
Abbreviations: ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blockers, BMI Body Mass Index; BP blood pressure, CVD cardiovascular disease, HbA1c glycated hemoglobin, HTN hypertension, LDL-low-density lipoproteins, Rx prescription
aPoint-of-care alert for specified drug class fired at the visit
bOffice visits defined as in-person encounters at a study clinic where the provider was a MD, PA, NP, or resident, and the encounter Evaluation & Management CPT code was in: 99201-99205; 99212-99215; 99243; 99385-99387; 99395-99397
cVisit counts are not mutually exclusive, e.g., if both types of BPA fired at a visit, the visit is counted in both the statin and ACEI/ARB columns. p-value from chi square test for independence between characteristic and outcome of Rx < = 2 days